Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$13.84-3.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — achieve ~23% revenue growth in FY27: FY27 rev est +6.3% vs 23% target.
Monte Rosa is developing new precision drugs that use the body to break down disease proteins. Analysts expect revenue growth of about 23% next year. The company aims to fund operations and capital spending into 2029. Positive clinical data and partnerships support future progress.
The company is loss-making with recent earnings misses. Litigation and management changes add risks. Revenue and profit growth remain uncertain. The stock trades at a high price-to-sales ratio with negative free cash flow.
The market prices in about 23% revenue growth next year and expects optionality from drug development. Our fair value is near the current price, reflecting cautious optimism. We differ by emphasizing the risks from losses and recent earnings misses.
Breaks if: cash and equivalents fall below levels needed to fund operations through 2029
Ensure sufficient cash and equivalents to fund planned operations and capital expenditures into 2029.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis state is cautious due to recent earnings misses and elevated near-term risks, despite potential sector tailwinds.
The market appears to have a low expectations gap, indicating that it may not be pricing in significant positive developments. GLUE's valuation is at a premium compared to peers, suggesting that investors expect some level of recovery or progress.
Fundamentals are likely to remain weak in the near term, with a high probability of missing earnings expectations. Management is focused on advancing clinical studies, but recent financial performance has not met industry standards.
The thesis hinges on management's ability to execute on clinical trials and the broader healthcare sector's performance. Key triggers include guidance updates and the performance of sector bellwethers.
The most important moves since the prior daily snapshot.
Signal changed from 'mixed' to 'cautious'.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: GFORCE-1 study results are negative or delayed beyond H2 2026
Breaks if: YoY revenue growth falls below ~23% in FY27
Over the next 1 to 3 years, GLUE's outlook will depend heavily on clinical advancements and market conditions. Not investment advice.